Search
Naratriptan
go.drugbank.com/drugs/DB00952ApprovedNaratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeXEN-D0101
go.drugbank.com/drugs/DB06020ExperimentalXEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.
Glycine
go.drugbank.com/drugs/DB00145ApprovedInvestigationalNutraceuticalVet approvedA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.
Pegademase
go.drugbank.com/drugs/DB00061ApprovedWithdrawnBovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.
Clobetasol
go.drugbank.com/drugs/DB11750ApprovedInvestigationalWithdrawnClobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.
Meticrane
go.drugbank.com/drugs/DB13284ApprovedIt has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647].
COVID19 s-vax loaded autologous dendritic cell vaccine
go.drugbank.com/drugs/DB15814ExperimentalThis vaccine was developed and tested by Beijing TIL Therapeutics. … These cells are then loaded with antigens produced by a virus or tumor cell and administered as a vaccine.
Urethane
go.drugbank.com/drugs/DB04827ApprovedWithdrawnUrethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.
Masoprocol
go.drugbank.com/drugs/DB00179InvestigationalThe compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. [PubChem]
Reproxalap
go.drugbank.com/drugs/DB16688Investigational[L32990] NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.[L32990] … Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis